Physiomics CEO Resignation and Leadership Transition

An announcement from Physiomics ( (GB:PYC) ) is now available.

Physiomics plc announced the resignation of CEO Peter Sargent, effective May 29, 2026, as he pursues other opportunities. The company is actively searching for a new CEO, with Dr. Jim Millen, the current Non-Executive Chairman, stepping in as Executive Chairman if needed to ensure continuity. Under Sargent’s leadership, Physiomics achieved significant revenue growth and contract wins, and the company is poised to continue its growth trajectory with a record level of contracted projects and advancements in its personalized medicine initiatives.

Spark’s Take on GB:PYC Stock

According to Spark, TipRanks’ AI Analyst, GB:PYC is a Underperform.

Physiomics’ stock score is primarily impacted by significant financial instability, including declining revenues and negative profit margins. Technical indicators reinforce a bearish outlook. While recent corporate events suggest potential growth pathways, current valuation issues and financial challenges remain significant obstacles.

To see Spark’s full report on GB:PYC stock, click here.

More about Physiomics

Physiomics plc is a company specializing in mathematical modelling, data science, and biometrics to support the development of new therapeutics and personalized medicine solutions. They combine expertise in Modelling & Simulation, Biostatistics, Data Science, and Bioinformatics to assist biotech and pharma companies in optimizing their drug development processes. Their proprietary Virtual Tumour technology has been instrumental in informing over 100 commercial projects, working with clients like Merck KGaA, Astellas, and Bicycle Therapeutics.

Average Trading Volume: 2,690,859

Technical Sentiment Signal: Sell

Current Market Cap: £1.14M

For detailed information about PYC stock, go to TipRanks’ Stock Analysis page.